Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1

Status

Recruiting 29Active not recruiting 18Suspended 4Terminated 3Withdrawn 2Not yet recruiting 2Completed 2

Sponsor Class

NIH 4

Study Type

Interventional 4

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 1Breast 1

Conditions

Leukemia, Myeloid, Acute 5Neoplasm Metastasis 4Myelodysplastic Syndromes 3Carcinoma, Renal Cell 3Triple Negative Breast Neoplasms 2Osteosarcoma 2Lymphoma, Follicular 2Glioblastoma 2Carcinoma, Hepatocellular 2Urinary Bladder Neoplasms 1Testicular Neoplasms 1Renal Insufficiency, Chronic 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Multiple Myeloma 1Melanoma 1Malignant Solid Neoplasm 1Lymphoma 1Lung Neoplasms 1Locally Recurrent Skin Squamous Cell Carcinoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hypogonadism 1HTLV-I Infections 1GATA2 Deficiency 1Eyelid Squamous Cell Carcinoma 1Colorectal Neoplasms 1

Interventions

Specimen Handling 4Biopsy 4Magnetic Resonance Spectroscopy 3vactosertib 1trastuzumab deruxtecan 1trastuzumab biosimilar HLX02 1pegamotecan 1neratinib 1ipatasertib 1fludarabine phosphate 1binimetinib 1aldesleukin 1X-Rays 1Trastuzumab 1Taxes 1Surveys and Questionnaires 1Phantoms, Imaging 1Paclitaxel 1PF-05280014 1Ontruzant 1Ogivri 1Nivolumab 1NUC-1031 1N-acetylcochinol-O-phosphate 1Ipilimumab 1Interleukin-2 1IL32 protein, human 1Gemcitabine 1Cyclophosphamide 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Suspended × Neoplasm Metastasis × Specimen Handling × Clear all
NCT05554380 2026-05-22

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Suspended
33 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05372614 2026-05-18

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

National Cancer Institute (NCI)

Phase 1 Suspended
33 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT04840589 2026-05-13

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

National Cancer Institute (NCI)

Phase 1 Suspended
66 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms

NCT05111561 2026-05-13

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Breast

Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡